Corebridge Financial Inc. lessened its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 5.1% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 199,154 shares of the biotechnology company’s stock after selling 10,761 shares during the period. Corebridge Financial Inc.’s holdings in Arrowhead Pharmaceuticals were worth $3,744,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of ARWR. State Street Corp raised its position in shares of Arrowhead Pharmaceuticals by 8.8% in the 3rd quarter. State Street Corp now owns 6,354,331 shares of the biotechnology company’s stock worth $123,083,000 after acquiring an additional 516,569 shares in the last quarter. Geode Capital Management LLC increased its holdings in Arrowhead Pharmaceuticals by 0.9% in the third quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company’s stock worth $57,426,000 after purchasing an additional 26,171 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Arrowhead Pharmaceuticals by 1.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,017,720 shares of the biotechnology company’s stock valued at $19,133,000 after buying an additional 10,785 shares during the period. abrdn plc boosted its holdings in shares of Arrowhead Pharmaceuticals by 12.2% during the 4th quarter. abrdn plc now owns 450,075 shares of the biotechnology company’s stock worth $8,461,000 after buying an additional 48,929 shares in the last quarter. Finally, Privium Fund Management B.V. boosted its holdings in shares of Arrowhead Pharmaceuticals by 14.2% during the 4th quarter. Privium Fund Management B.V. now owns 380,586 shares of the biotechnology company’s stock worth $7,155,000 after buying an additional 47,230 shares in the last quarter. Institutional investors own 62.61% of the company’s stock.
Insiders Place Their Bets
In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 11,520 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $19.05, for a total value of $219,456.00. Following the completion of the transaction, the chief executive officer now owns 3,764,252 shares in the company, valued at $71,709,000.60. This represents a 0.31 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Patrick O’brien sold 29,184 shares of Arrowhead Pharmaceuticals stock in a transaction on Monday, January 6th. The stock was sold at an average price of $19.82, for a total value of $578,426.88. Following the sale, the chief operating officer now owns 535,201 shares in the company, valued at $10,607,683.82. The trade was a 5.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 286,317 shares of company stock valued at $5,049,735. Corporate insiders own 4.30% of the company’s stock.
Analysts Set New Price Targets
Get Our Latest Stock Analysis on ARWR
Arrowhead Pharmaceuticals Stock Up 0.1 %
Shares of NASDAQ:ARWR opened at $13.82 on Monday. The business’s 50 day moving average is $18.13 and its 200 day moving average is $19.60. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $13.66 and a 12-month high of $30.41. The stock has a market cap of $1.90 billion, a price-to-earnings ratio of -2.67 and a beta of 0.92. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27.
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) last posted its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.97). On average, sell-side analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.
See Also
- Five stocks we like better than Arrowhead Pharmaceuticals
- What is an Earnings Surprise?
- Venezuelan Tariffs Could Power These 3 Diesel-Driven Winners
- How Technical Indicators Can Help You Find Oversold Stocks
- MarketBeat Week in Review – 03/24 – 03/28
- What to Know About Investing in Penny Stocks
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report).
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.